EGFR and nasopharyngeal carcinoma: Unlike anti-angiogenic therapy, the combination of anti-EGFR drugs, such as Nimotuzumab, and Cetuximab, with chemoradiotherapy have been proved to maximize the survival of stage II-IVb NPC patients29.